202 related articles for article (PubMed ID: 30560892)
1. High-resolution deconstruction of evolution induced by chemotherapy treatments in breast cancer xenografts.
Kim H; Kumar P; Menghi F; Noorbakhsh J; Cerveira E; Ryan M; Zhu Q; Ananda G; George J; Chen HC; Mockus S; Zhang C; Yang Y; Keck J; Karuturi RKM; Bult CJ; Lee C; Liu ET; Chuang JH
Sci Rep; 2018 Dec; 8(1):17937. PubMed ID: 30560892
[TBL] [Abstract][Full Text] [Related]
2. Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.
Goetz MP; Kalari KR; Suman VJ; Moyer AM; Yu J; Visscher DW; Dockter TJ; Vedell PT; Sinnwell JP; Tang X; Thompson KJ; McLaughlin SA; Moreno-Aspitia A; Copland JA; Northfelt DW; Gray RJ; Hunt K; Conners A; Sicotte H; Eckel-Passow JE; Kocher JP; Ingle JN; Ellingson MS; McDonough M; Wieben ED; Weinshilboum R; Wang L; Boughey JC
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376176
[TBL] [Abstract][Full Text] [Related]
3. A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition.
Shee K; Wells JD; Ung M; Hampsch RA; Traphagen NA; Yang W; Liu SC; Zeldenrust MA; Wang L; Kalari KR; Yu J; Boughey JC; Demidenko E; Kettenbach AN; Cheng C; Goetz MP; Miller TW
Clin Cancer Res; 2020 Jan; 26(1):159-170. PubMed ID: 31558472
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
[TBL] [Abstract][Full Text] [Related]
5. The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.
Sarwar M; Syed Khaja AS; Aleskandarany M; Karlsson R; Althobiti M; Ødum N; Mongan NP; Dizeyi N; Johnson H; Green AR; Ellis IO; Rakha EA; Persson JL
Oncogene; 2019 Jan; 38(3):375-389. PubMed ID: 30104711
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
[TBL] [Abstract][Full Text] [Related]
7. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017
[No Abstract] [Full Text] [Related]
8. Vitamin D analogues exhibit antineoplastic activity in breast cancer patient-derived xenograft cells.
Ferronato MJ; Nadal Serrano M; Arenas Lahuerta EJ; Bernadó Morales C; Paolillo G; Martinez-Sabadell Aliguer A; Santalla H; Mascaró M; Vitale C; Fall Y; Arribas J; Facchinetti MM; Curino AC
J Steroid Biochem Mol Biol; 2021 Apr; 208():105735. PubMed ID: 32784045
[TBL] [Abstract][Full Text] [Related]
9. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
10. Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts.
Gwynne WD; Hallett RM; Girgis-Gabardo A; Bojovic B; Dvorkin-Gheva A; Aarts C; Dias K; Bane A; Hassell JA
Oncotarget; 2017 May; 8(19):32101-32116. PubMed ID: 28404880
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
12. The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.
Hansen SN; Ehlers NS; Zhu S; Thomsen MB; Nielsen RL; Liu D; Wang G; Hou Y; Zhang X; Xu X; Bolund L; Yang H; Wang J; Moreira J; Ditzel HJ; Brünner N; Schrohl AS; Stenvang J; Gupta R
BMC Genomics; 2016 Jun; 17():442. PubMed ID: 27277198
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of casein kinase 1δ in breast cancer.
Rosenberg LH; Lafitte M; Quereda V; Grant W; Chen W; Bibian M; Noguchi Y; Fallahi M; Yang C; Chang JC; Roush WR; Cleveland JL; Duckett DR
Sci Transl Med; 2015 Dec; 7(318):318ra202. PubMed ID: 26676609
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.
Turner TH; Alzubi MA; Sohal SS; Olex AL; Dozmorov MG; Harrell JC
Breast Cancer Res Treat; 2018 Jul; 170(2):221-234. PubMed ID: 29532339
[TBL] [Abstract][Full Text] [Related]
15. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer.
Dunne M; Dou YN; Drake DM; Spence T; Gontijo SML; Wells PG; Allen C
J Control Release; 2018 Jul; 282():35-45. PubMed ID: 29673642
[TBL] [Abstract][Full Text] [Related]
17. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
[TBL] [Abstract][Full Text] [Related]
18. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
19. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
20. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.
Gómez-Miragaya J; Palafox M; Paré L; Yoldi G; Ferrer I; Vila S; Galván P; Pellegrini P; Pérez-Montoyo H; Igea A; Muñoz P; Esteller M; Nebreda AR; Urruticoechea A; Morilla I; Pernas S; Climent F; Soler-Monso MT; Petit A; Serra V; Prat A; González-Suárez E
Stem Cell Reports; 2017 May; 8(5):1392-1407. PubMed ID: 28457887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
